Stem cell therapy advances: MSCs show potential in managing COVID-19 and influenza infections
Bioanalytical readings return to normal following MSC administration, emphasizing the potential in managing COVID-19-induced complications. MSC therapy offers a potential solution for infection with the influenza virus, which is responsible for historical pandemics and epidemics, and remains a global health concern
StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
StemCyte announced today that its Hematopoietic Progenitor Cell Cord Blood therapy (HPC Cord Blood) has officially obtained the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Long COVID-19 syndrome
Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19
MSC-treated group showed significantly lower risk of mortality than the control group (p = 0.03). No statistical significance was observed on the incidence of AEs
Novel stem cell therapy using technology from mRNA COVID-19 vaccines may stimulate natural repair in treatment of chronic and acute liver disease
New research from Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine’s Center for Regenerative Medicine (CReM) found evidence that a novel stem cell treatment, using mRNA successfully used to produce the COVID-19 vaccines.
